Edition:
United Kingdom

Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint


Thursday, 19 Oct 2017 

Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​.Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance.